Home
overview
Obesity has been increasing in the western world at such an alarming rate that it now constitutes one of the most important health risks today, due to the number of health complications associated with the condition. SMi has therefore identified a need to look at obesity and the disorders related to it in more depth. This conference aims to look at the causes of obesity, diseases related to obesity and ongoing research into anti-obesity drugs. The conference will also assess the success of anti-obesity drugs already released onto the market. Such initiatives are essential if the obesity epidemic is to be curbed.

Benefits of Attending
· Identify the key issues surrounding obesity
· The obese phenotype: discover the role of glucocorticoids
· Targets for obesity: assess the rationale for the 5HT2C receptor
· Lipid metabolism: consider the role of human growth hormone
· Melanin Concentrating Hormone: learn about the MCH1-R antagonists for the treatment of obesity
· Obesity & diabetes: establish how they are linked

A unique opportunity to meet and learn from leading industry experts including:
Dr Richard Carr, Scientific Vice President, Novo Nordisk
Dr Andrew Swick, Manager Cardiovascular & Metabolic Diseases - Obesity, Pfizer
Dr Andrew Nichols, Head, Metabolic Diseases, Millennium Pharmaceuticals
Dr Colin Dourish, Senior Vice President, Research, Vernalis
Dr Mark Heffernan, Research Manager, Metabolic Pharmaceuticals
Dr Robin Buckingham, Associate Director, European Clinical Development & Medical Affairs, GlaxoSmithKline
Dr Patrizia Caldirola, Project Leader, Biovitrum
Dr Richard Pittner, Senior Director, Cell & Molecular Biology, Amylin Pharmaceuticals

“Useful thought into cutting-edge science”
“Very informative, well organised and the staff were very courteous”
Previous SMi delegates, Pharmaceutical Conferences, 2002

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Richard Carr

Dr Richard Carr, Scientific Vice President, Novo Nordisk

9:10 NOVEL APPROACHES TO THE DISCOVERY OF ANTI-OBESITY DRUGS

Dr Andrew Nichols

Dr Andrew Nichols, Head, Metabolic Diseases, Millennium Pharmaceuticals

  • Body weight regulation – how can we modify it?
  • Genomics approaches to the discovery of novel targets for the treatment of obesity
  • Target validation – from discovery through the clinic
  • Drug discovery in obesity – what does it take to be successful?
  • The challenges of taking novel mechanism anti-obesity drugs into the clinic
  • 9:40 THE CLINICAL NEED FOR EFFECTIVE ANTI-OBESITY DRUGS

  • Obesity as a disease
  • The evidence for benefit from weight loss
  • Dietary interventions – how effective are they?
  • Lifestyle interventions – how effective are they?
  • Bariatric surgery – an increasingly available option
  • Integrating pharmacotherapy into clinical practice
  • Dr Nick Finer

    Dr Nick Finer, Senior Research Associate, Cambridge University

    10:20 PHENOTYPE-FIRST SCREENS FOR THE IDENTIFICATION OF OBESITY GENES

    Dr Guenter Brönner

    Dr Guenter Brönner, Director Target ID, DeveloGen

  • Obesity as multifactorial disease
  • Genome-wide screening for targets
  • Selection and validation of novel targets
  • Potential impact on the understanding and treatment of obesity and related disorders
  • 11:00 Morning Coffee

    11:20 APPETITE SUPPRESSANTS

    Dr Colin Dourish

    Dr Colin Dourish, Senior Vice President, Research, Vernalis

  • Appetite and 5-HT receptor mechanisms
  • Rationale for the 5HT2c receptor as a target for obesity
  • Discovery of selective 5HT2c receptor agonists
  • Next steps in development
  • 12:00 5-HT6 RECEPTOR ANTAGONISM

    Dr Patrizia Caldirola

    Dr Patrizia Caldirola, Project Leader, Biovitrum

  • 5-HT6 receptor background
  • Rationale for 5-HT6 receptor antagonism and obesity
  • supporting evidence from 5-HT6 receptor knock-out mice
  • Effect of selective 5-HT6 receptor antagonists on food intake and body weight regulation
  • 5-HT6 receptor antagonists: mono therapy or in combination with other anti-obesity agents
  • 12:40 Networking Lunch

    14:00 A NOVEL APPROACH TO ALTERING FAT METABOLISM

    Dr Mark Heffernan

    Dr Mark Heffernan, Research Manager, Metabolic Pharmaceuticals

  • The role of human growth hormone in lipid metabolism
  • Peptide fragments of human growth hormone
  • The development of clinical trials for the drug AOD9604
  • Moving forward – future developments for AOD9604
  • 14:40 AKOKINE

    Dr Hans-Peter Guler

    Dr Hans-Peter Guler, Vice President, Clinical Sciences, Regeneron Pharmaceuticals

  • Serendipitous findings with ciliary neurotrophic factor (CNTF)
  • From CNTF to AXOKINE
  • Signalling mechanisms of AXOKINE
  • AXOKINE in animal models of obesity
  • AXOKINE causes weight loss in obese people
  • 15:20 Afternoon Tea

    15:40 MELANIN CONCENTRATING HORMONE

    Dr Carlos Forray

    Dr Carlos Forray, Director, Clinical Science, Synaptic Pharmaceutical Corporation

  • The role of MCH and the lateral hypothalamus in the homeostasis of energy balance
  • MCH receptors
  • Evidence from gene deletion studies and genetic models of obesity
  • MCH1-R antagonists for the treatment of obesity
  • A role for MCH in the regulation of mood and emotion
  • 16:20 PANEL DISCUSSION - WHAT WOULD BE THE PROFILE FOR THE IDEAL ANTI-OBESITY DRUG?

    17:00 Chairman’s Closing Remarks and Close Of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman’s Opening Remarks

    Prof Jonathan Arch

    Prof Jonathan Arch, Professorial Research Fellow & Deputy Director of Metabolic Research, Clore Laboratory, University of Buckingham

    9:10 HORMONAL REGULATION OF BODY WEIGHT

    Dr Andrew Swick

    Dr Andrew Swick, Manager, Cardiovascular & Metabolic Diseases – Obesity, Pfizer

  • Mechanism of glucocorticoid action
  • Glucocorticoids in animal models of obesity
  • In vitro activity of glucocorticoid receptor antagonists
  • Effects of glucocorticoid receptor antagonists in vivo
  • Interrelationship between glucocorticoids and leptin
  • 9:40 CIRCULATING GUT PEPTIDE HORMONES – SATIETY FACTORS?

    Dr Richard Pittner

    Dr Richard Pittner, Senior Director, Cell & Molecular Biology, Amylin Pharmaceuticals

  • Amylin
  • GLP-1
  • PYY [3-36]
  • 10:20 AFFERENT SIGNALLING TO THE BRAIN

    Dr Simon Luckman

    Dr Simon Luckman, Lecturer, University of Manchester

  • The brainstem integrates direct and indirect regulators of food
  • Brainstem efferents may signal separate or overlapping modalities
  • Nutrients and hormones signal to the brain
  • Hormones may act on neuronal networks
  • 11:00 Morning Coffee

    11:20 PANEL DISCUSSION - HOW SHOULD WE VALIDATE TARGETS PRE-CLINICALLY FOR THEIR ABILITY TO DELIVER THE IDEAL ANTI-OBESITY DRUG?

    12:00 INFLAMMATION: THE COMMON SOIL OF TYPE II DIABETES AND CARDIOVASCULAR DISEASE

    Dr Robin Buckingham

    Dr Robin Buckingham, Associate Director, European Clinical Development & Medical Affairs, GlaxoSmithKline

  • Recent epidemiological data points to low-grade inflammation as being predictive for type II diabetes and CV disease
  • The inflammatory axis may comprise adipose tissue, the liver and the target tissues and organs
  • Cytokines, adipokines and acute phase inflammatory proteins, such as C-reactive protein, may be the key signalling molecules in this axis
  • Further data point to powerful anti-inflammatory effects of thiazolidinedione drugs, suggesting that these agents may not only be effective remedies for controlling blood glucose, but may also delay or even prevent both type II diabetes and its CV sequelae
  • 12:40 Networking Lunch

    14:00 FETAL ORIGINS OF OBESITY AND TYPE II DIABETES

    Dr Andrew Eisen

    Dr Andrew Eisen, Head, Metabolic Diseases Program, CuraGen

  • How are obesity and diabetes inherited?
  • Genes and environment
  • Of mice and (wo)men
  • Insights from gestational diabetes
  • The potential of pre-natal treatment
  • 14:40 DIABESITY TARGET IDENTIFICATION AND VALIDATION USING LARGE SCALE MOUSE KNOCKOUT ANALYSIS

    Dr Mark Moore

    Dr Mark Moore, Chief Scientific Officer, Deltagen

  • Single gene knockouts in mice offer a unique opportunity to analyse biological pathways involved in both diabetes and obesity
  • The number of genes involved in diabesity is far greater than previously assumed
  • Large scale knockouts allow for the concurrent and consistent analysis of multiple genes
  • Specific criteria must be developed to define the ‘best’ target
  • 15:20 Afternoon Tea

    15:40 SEARCHING FOR NEW DRUG TARGETS IN OBESITY AND DIABETES

    Dr Johannes Grosse

    Dr Johannes Grosse, Director Metabolic, Ingenium Pharmaceuticals

  • Random mutagenesis in the mouse
  • Forward genetics
  • Reverse genetics
  • Gene expression analysis
  • 16:20 FITNESS NOT FATNESS

    Dr Louis Crowe

    Dr Louis Crowe, Medical Director, Bio-Medical Research

  • Cardiovascular fitness is the missing element in the pharmacological approach to obesity
  • Present exercise offerings have failed the obese
  • A passive exercise device for the obese patient
  • Its equivalence to voluntary aerobic exercise
  • Clinical trial results
  • 17:00 Chairman’s Closing Remarks and Close Of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.